Long-Term Safety and Efficacy of Fremanezumab for the Prevention of Cluster Headache

- Cluster Headache
- Terminated

Study Title: A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache

Teva Identifier: TV48125-CNS-30058 | 2016-003172-43

ClinicalTrials.gov Identifier: NCT03107052

Study Status: Terminated

Trial Condition(s): Cluster Headache

Interventions: Drug: Fremanezumab

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult, Older Adult

Age Range: 18 Years to 70 Years

Trial Duration: April 27, 2017 - June 11, 2019

Phase: Phase 3

Additional info

Synopsis

Plain Language Summary

Study Type

Interventional